Immunocellular Therapeutics Limited (NYSEAMERICAN:IMUC) Short Interest Increased By 0.01%

February 14, 2018 - By Winifred Garcia

 Immunocellular Therapeutics Limited (NYSEAMERICAN:IMUC) Short Interest Increased By 0.01%

The stock of Immunocellular Therapeutics Limited (NYSEAMERICAN:IMUC) registered an increase of 0.01% in short interest. IMUC’s total short interest was 1.71 million shares in February as published by FINRA. Its up 0.01% from 1.71M shares, reported previously. With 1.31 million shares average volume, it will take short sellers 1 days to cover their IMUC’s short positions. The short interest to Immunocellular Therapeutics Limited’s float is 49.66%.

The stock increased 14.58% or $0.0331 during the last trading session, reaching $0.2601. About 5.13M shares traded or 81.29% up from the average. ImmunoCellular Therapeutics, Ltd. (NYSEAMERICAN:IMUC) has declined 86.26% since February 14, 2017 and is downtrending. It has underperformed by 102.96% the S&P500.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune therapies for the treatment of various cancers. The company has market cap of $9.15 million. The Company’s lead product candidate is ICT-107, a dendritic cell immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). It currently has negative earnings. The firm is also developing ICT-140, a DC immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.

Another recent and important ImmunoCellular Therapeutics, Ltd. (NYSEAMERICAN:IMUC) news was published by which published an article titled: “ImmunoCellular Therapeutics Announces Update on Financial Condition” on February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.